Restricted accessResearch articleFirst published online 2015-06
No Synergistic Effect of Cotransplantation of MSC and Ex Vivo TPO-Expanded CD34 + Cord Blood Cells on Platelet Recovery and Bone Marrow Engraftment in NOD SCID Mice
After cord blood (CB) transplantation, early platelet recovery in immune-deficient mice is obtained by expansion of CB CD34+ cells with thrombopoietin (TPO) as single growth factor. Moreover, improvement of hematopoietic engraftment has been shown by cotransplantation of mesenchymal stem cells (MSC). We investigated whether a combination of both approaches would further enhance the outcome of CB transplantation in NOD SCID mice. NOD SCID mice were transplanted with either CB CD34+ cells, CD34+ cells with MSC, TPO-expanded CD34+ cells or TPO-expanded CD34+ cells with MSC. We analyzed human platelet recovery in the peripheral blood (PB) from day 4 after transplantation onward and human bone marrow (BM) engraftment at week 6. The different transplants were assessed in vitro for their migration capacity and expression of CXCR4. TPO expansion improved the early platelet recovery in the PB of the mice. Cotransplantation of MSC with CD34+ cells improved BM engraftment and platelet levels in the PB 6 weeks after transplantation. Combining TPO expansion and MSC cotransplantation, however, neither resulted in a more efficient early platelet recovery, nor in a better BM engraftment, nor even very low or absent BM engraftment occurred. In vitro, MSC boosted the migration of CD34+ cells, suggesting a possible mechanism for the increase in engraftment. Our results show that cotransplantation of MSC with TPO-expanded CD34+ cells at most combines, but does not increase the separate advantages of these different strategies. A combination of both strategies even adds a risk of non engraftment.
Get full access to this article
View all access options for this article.
References
1.
BallenKK, GluckmanE and BroxmeyerHE. (2013). Umbilical cord blood transplantation: the first 25 years and beyond. Blood, 122:491–498.
2.
BallenKK, KorethJ, ChenYB, DeyBR and SpitzerTR. (2012). Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood, 119:1972–1980.
3.
FuchsE, O'DonnellPV and BrunsteinCG. (2013). Alternative transplant donor sources: is there any consensus?. Curr Opin Oncol, 25:173–179.
BrunsteinCG, GutmanJA, WeisdorfDJ, WoolfreyAE, DeForTE, GooleyTA, VernerisMR, AppelbaumFR, WagnerJE and DelaneyC. (2010). Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood, 116:4693–4699.
6.
EapenM, RubinsteinP, ZhangM-J, StevensC, KurtzbergJ, ScaradavouA, LoberizaFR, ChamplinRE, KleinJP and HorowitzMM. (2007). Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, 369:1947–1954.
7.
RochaV, LabopinM, SanzG, ArceseW, SchwerdtfegerR, BosiA, JacobsenN, RuutuT, de LimaM and FinkeJ. (2004). Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med, 351:2276–2285.
8.
DanbyR and RochaV. (2014). Current Strategies to Improve Engraftment in Cord Blood Transplantation. J Stem Cell Res Ther, 4:2
9.
KellyS, SolaC, De LimaM and ShpallE. (2009). Ex vivo expansion of cord blood. Bone Marrow Transplantat, 44:673–681.
10.
TungS, ParmarS, RobinsonS, De LimaM and ShpallE. (2010). Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol, 23:245–257.
11.
MattiaG, MilazzoL, VulcanoF, PascuccioM, MacioceG, HassanHJ and GiampaoloA. (2008). Long–term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin–amplified in clinical grade serum–free culture. Exp Hematol, 36:244–252.
12.
SchipperLF, BrandA, FibbeWE and Van HensbergenY. (2012). Functional characterization of TPO‐expanded CD34+ cord blood cells identifies CD34–CD61– cells as platelet‐producing cells early after transplantation in NOD/SCID mice and rCD34+ cells as CAFC colony‐forming cells. Stem Cells, 30:988–996.
13.
van HensbergenY, SchipperLF, BrandA, SlotMC, WellingM, NautaAJ and FibbeWE. (2006). Ex vivo culture of human CD34+ cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a NOD/SCID mouse model. Exp Hematol, 34:943–950.
14.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
ChamberlainG, FoxJ, AshtonB and MiddletonJ. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25:2739–2749.
17.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI and FiskNM. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98:2396–2402.
18.
NoortWA, KruisselbrinkAB, KrugerM, van BezooijenRL, de PausRA, HeemskerkMH, LöwikCW, FalkenburgJ, WillemzeR and FibbeWE. (2002). Mesenchymal stem cells promote engraftment of human umbilical cord blood–derived CD34+ cells in NOD/SCID mice. Exp Hematol, 30:870–878.
19.
NautaAJ and FibbeWE. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110:3499–3506.
20.
DuijvesteinM, VosACW, RoelofsH, WildenbergME, WendrichBB, VerspagetHW, Kooy-WinkelaarEM, KoningF, ZwagingaJJ and FidderHH. (2010). Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut, 59:1662–1669.
21.
SunL, WangD, LiangJ, ZhangH, FengX, WangH, HuaB, LiuB, YeS and HuX. (2010). Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum, 62:2467–2475.
22.
ChristopeitM, SchendelM, FöllJ, MüllerL, KeysserG and BehreG. (2007). Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia, 22:1062–1064.
23.
KebriaeiP, IsolaL, BahceciE, HollandK, RowleyS, McGuirkJ, DevettenM, JansenJ, HerzigR and SchusterM. (2009). Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant, 15:804–811.
24.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME and RembergerM. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
25.
LucchiniG, IntronaM, DanderE, RovelliA, BalduzziA, BonanomiS, SalvadèA, CapelliC, BelottiD and GaipaG. (2010). Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant, 16:1293–1301.
26.
Pérez-SimonJA, Lopez-VillarO, AndreuEJ, RifonJ, MuntionS, CampeloMD, Sánchez-GuijoFM, MartinezC, ValcarcelD and del CañizoC. (2011). Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica, 96:1072–1076.
27.
PrasadVK, LucasKG, KleinerGI, TalanoJAM, JacobsohnD, BroadwaterG, MonroyR and KurtzbergJ. (2011). Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant, 17:534–541.
28.
RingdenO and Le BlancK. (2011). Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol, 24:65–72.
29.
BaronF, LechanteurC, WillemsE, BruckF, BaudouxE, SeidelL, VanbellinghenJ-F, HafraouiK, LejeuneM and GothotA. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant, 16:838–847.
30.
KuzminaLA, PetinatiNA, ParovichnikovaEN, LubimovaLS, GribanovaEO, GaponovaTV, ShipounovaIN, ZhironkinaOA, BigildeevAE and SvinarevaDA. (2011). Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease—a phase II study. Stem Cells Int 2012: Article ID. 968213.
31.
FriedmanR, BetancurM, BoisselL, TuncerH, CetruloC and KlingemannH. (2007). Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant, 13:1477–1486.
32.
HiwaseSD, DysonPG, ToLB and LewisID. (2009). Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient mice. Stem Cells, 27:2293–2300.
33.
in 't AnkerPS, NoortWA, KruisselbrinkAB, ScherjonSA, BeekhuizenW, WillemzeR, KanhaiHH and FibbeWE. (2003). Nonexpanded primary lung and bone marrow–derived mesenchymal cells promote the engraftment of umbilical cord blood–derived CD34+ cells in NOD/SCID mice. Exp Hematol, 31:881–889.
34.
KimD-W, ChungY-J, KimT-G, KimY-L and OhI-H. (2004). Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation. Blood, 103:1941–1948.
35.
MasudaS, AgeyamaN, ShibataH, ObaraY, IkedaT, TakeuchiK, UedaY, OzawaK and HanazonoY. (2009). Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol, 37:1250–1257.
36.
BallLM, BernardoME, RoelofsH, LankesterA, CometaA, EgelerRM, LocatelliF and FibbeWE. (2007). Cotransplantation of ex vivo–expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood, 110:2764–2767.
37.
MacmillanM, BlazarB, DeForT and WagnerJ. (2008). Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I–II clinical trial. Bone Marrow Transplant, 43:447–454.
38.
LeeS, LeeM, YooK, KimD, SonM, SungK, CheuhH, ChoiS, OhW and YangY. (2013). Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant, 48:1040–1045.
39.
WuK-H, SheuJ-N, WuH-P, TsaiC, SieberM, PengC-T and ChaoY-H. (2013). Cotransplantation of umbilical cord–derived mesenchymal stem cells promote hematopoietic engraftment in cord blood transplantation: a pilot study. Transplantation, 95:773–777.
SchipperLF, Van HensbergenY, FibbeWE and BrandA. (2007). A sensitive quantitative single‐platform flow cytometry protocol to measure human platelets in mouse peripheral blood. Transfusion, 47:2305–2314.
42.
van der GardeM, van HensbergenY, BrandA, SlotMC, de Graaf-DijkstraA, MulderA, WattSM and ZwagingaJJ. (2015). Thrombopoietin treatment of one graft in a double cord blood transplant provides early platelet recovery while contributing to long term engraftment in NSG mice. Stem Cells Dev, 24:67–76.
43.
PeledT, ShohamH, AschengrauD, YackoubovD, FreiG, Rosenheimer GN, LerrerB, CohenHY, NaglerA and FibachE. (2012). Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol, 40:342–355.
44.
QuesenberryPJ and BeckerPS. (1998). Stem cell homing: rolling, crawling, and nesting. Proc Natl Acad Sci USA, 95:15155–15157.
45.
VermeulenM, Le PesteurF, GagneraultM-C, MaryJ-Y, SaintenyF and LepaultF. (1998). Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood, 92:894–900.
46.
VoermansC, RoodP, HordijkP, GerritsenW and Van Der SchootC. (2000). Adhesion molecules involved in transendothelial migration of human hematopoietic progenitor cells. Stem Cells, 18:435–443.
47.
SchipperLF, BrandA, ReniersN, MeliefCJ, WillemzeR and FibbeWE. (2003). Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood. Exp Hematol, 31:324–330.
48.
AngelopoulouM, NovelliE, GroveJE, RinderHM, CivinC, ChengL and KrauseDS. (2003). Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol, 31:413–420.
49.
KangSK, ShinIS, KoMS, JoJY and RaJC. (2012). Journey of mesenchymal stem cells for homing: strategies to enhance efficacy and safety of stem cell therapy. Stem Cells Int 2012: Article ID. 342968.
50.
SchrepferS, DeuseT, ReichenspurnerH, FischbeinM, RobbinsR and PelletierM. (2007). Stem cell transplantation: the lung barrier. Transplant Proc, 39:573–576.
51.
WattSM, GulloF, van der GardeM, MarkesonD, CamiciaR, KhooCP and ZwagingaJJ. (2013). The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Br Med Bull, 2013:1–29.
52.
TurnerML, MasekLC, HardyCL, ParkerAC and SweetenhamJW. (1998). Comparative adhesion of human haemopoietic cell lines to extracellular matrix components, bone marrow stromal and endothelial cultures. Br J Haematol, 100:112–122.
53.
VoermansC, GerritsenWR, von dem BorneAE and van der SchootCE. (1999). Increased migration of cord blood-derived CD34+ cells, as compared to bone marrow and mobilized peripheral blood CD34+ cells across uncoated or fibronectin-coated filters. Exp Hematol, 27:1806–1814.
54.
de LimaM, McNieceI, RobinsonSN, MunsellM, EapenM, HorowitzM, AlousiA, SalibaR, McMannisJD and KaurI. (2012). Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med, 367:2305–2315.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
